22934-24-3

Basic information

• Product Name: 3-nitro-6-hydroxy-2,4-dimethylpyridine
• Synonyms: 3-nitro-6-hydroxy-2,4-dimethylpyridine;4,6-Dimethyl-5-nitro-pyridin-2-ol;4,6-dimethyl-5-nitro-2(1H)-Pyridinone
• CAS NO: 22934-24-3
• Molecular Formula: C₇H₈N₂O₃
• Molecular Weight: 168.15002
• Mol File: 22934-24-3.mol
• Article Data: 4

Chemical Properties

• Melting Point: 251 °C
• Boiling Point: 323.5±35.0 °C(Predicted)
• Appearance: /
• Density: 1.29±0.1 g/cm3(Predicted)
• PKA: 8.20±0.10(Predicted)
• CAS DataBase Reference: 3-nitro-6-hydroxy-2,4-dimethylpyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-nitro-6-hydroxy-2,4-dimethylpyridine(22934-24-3)
• EPA Substance Registry System: 3-nitro-6-hydroxy-2,4-dimethylpyridine(22934-24-3)

Safety Data

• Hazardous Substances Data: 22934-24-3(Hazardous Substances Data)

Upstream product

• 89977-22-0 2-hydroxy-4,6-dimethyl-5-nitro-nicotinic acid 
• 5407-87-4 2-Amino-4,6-dimethylpyridine 
• 769-28-8 3-Cyano-4,6-dimethyl-2(1H)-pyridon 
• 22934-22-1 3-Nitro-6-amino-2,4-dimethyl-pyridin 

Downstream Products

• 1073-21-8 3-amino-2,4-dimethylpyridine 

Relevant articles and documents

Synthesis and structure-activity relationships of N3-pyridylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists

A series of N3-pyridylpyrazinones was investigated as corticotropin-releasing factor-1 receptor antagonists. It was observed that the binding affinity of analogues containing a pyridyl group was influenced not only by the substitution pattern on the pyridyl group, but also by the pKa of the pyridyl nitrogen. Analogues containing a novel 6-(difluoromethoxy)-2,5-dimethylpyridin-3-amine group were among the most potent N3-pyridylpyrazinones synthesized. The synthesis and SAR of N3-pyridylpyrazinones is described herein.

OGA INHIBITOR COMPOUNDS

The present invention relates to O-GIcNAc hydrolase (OGA) inhibitors of formula (I). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations.